Haleon (HLN) EBT (2021 - 2025)

Haleon's (HLN) quarterly EBT came in at $1.4 billion in Q4 2025, down 20.3% on a QoQ basis from $1.8 billion in Q4 2023.

Haleon (HLN) EBT (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of EBT data on file, last reported at $1.4 billion in Q4 2025.

Quarterly EBT changed N/A year-over-year to $1.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 billion (changed N/A YoY) and the FY2025 annual result came in at $2.9 billion, up 17.24% from the prior year.
EBT eased to $1.4 billion in Q4 2025, from $1.8 billion in the prior quarter.
In the past five years, EBT ranged from a high of $1.8 billion in Q4 2023 to a low of $523.1 million in Q2 2023.
A 4-year average of $1.3 billion and a median of $1.4 billion in 2025 frame the typical range for EBT.
Annual changes were most pronounced in 2022 — EBT slipped 4.87% — and 2023, when it climbed 13.37%.
Tracing HLN's EBT over 4 years: stood at $1.7 billion in 2021, then dropped by 4.87% to $1.6 billion in 2022, then rose by 13.37% to $1.8 billion in 2023, then declined by 20.3% to $1.4 billion in 2025.
The last three EBT figures came in at $1.4 billion (Q4 2025), $1.8 billion (Q4 2023), and $523.1 million (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Haleon	43.71 Bn	42.75 Bn	-	-
2	Teva Pharmaceutical Industries	43.11 Bn	39.45 Bn	2.15 Bn	-455.00 Mn
3	Zoetis	31.62 Bn	29.94 Bn	1.05 Bn	866.00 Mn
4	Takeda Pharmaceutical	28.72 Bn	22.92 Bn	5.10 Bn	1.02 Bn
5	United Therapeutics	22.33 Bn	19.67 Bn	683.80 Mn	372.70 Mn
6	Viatris	18.83 Bn	17.95 Bn	1.46 Bn	-64.00 Mn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	162.20 Mn
8	Elanco Animal Health	12.10 Bn	11.57 Bn	798.00 Mn	56.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.25 Bn	7.60 Bn	397.90 Mn	-1.88 Mn

Download Data